Trial Profile
A Multi-center, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naive Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Taspoglutide (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Roche
- 16 Jun 2009 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov